Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020

ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the registration statement on Form S-4 containing a joint preliminary proxy statement/prospectus in connection with Aytu BioScience's proposed acquisition of Innovus Pharmaceuticals is now effective following the companies' filing with the U.S. Securities and Exchange Commission. With the effectiveness of Form S-4, Aytu and Innovus have set their respective special shareholder meetings for February 13, 2020 during which the companies' shareholders will vote on the merger agreement.

The registration statement containing the joint preliminary proxy statement/prospectus is available through the SEC's website at www.sec.gov and on Aytu BioScience's website in the Investor section.

The Aytu BioScience special meeting is scheduled for February 13, 2020 at 10:00 AM Mountain Time. The meeting will be held at Aytu BioScience's corporate headquarters, located at 373 Inverness Parkway, Suite 206 Englewood, CO 80112.

The Innovus Pharmaceuticals special meeting is also scheduled for February 13, 2020 at 8:00 AM Pacific Time. The meeting will be held at the Hyatt House San Diego, located at 10044 Pacific Mesa Boulevard, San Diego, CA 92121.

As announced on September 12, 2019, the companies signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing, including amounts owed from Innovus to Aytu under a promissory note (currently $1.35 million principal amount), payments to be made to warrant holders, changes in Innovus liabilities and working capital, and other adjustments. This initial consideration to Innovus common shareholders is currently estimated to consist of approximately 3.8 million shares of Aytu stock. Each Innovus common shareholder will also receive contingent value rights ("CVRs"), representing the right to receive additional consideration of up to an aggregate of $16 million, paid to in cash or stock at Aytu's option, over the next five years if certain revenue and profitability milestones are achieved.

Innovus generated over $24 million in revenue during the twelve-month period ended December 31 2019 (unaudited) and has achieved the initial revenue-based CVR milestone as specified in the merger agreement. Upon finalization and audit of Innovus' Q4 2019 revenue, Aytu expects to pay the $2M milestone payment. The milestone payment is payable in stock or cash at the company's option.

Through this combined entity, Aytu will expand into the $40 billion consumer healthcare market with a portfolio of over thirty-five consumer products competing in large therapeutic categories including diabetes, men's health, sexual wellness and respiratory health. This expanded product line broadens Aytu's portfolio beyond prescription therapeutics to enable wider revenue distribution, reduced seasonality associated with Aytu's seasonal antitussive/antihistamine product line, and higher revenue from an expanded base of proprietary products.

Combined, Aytu and Innovus products generated approximately $43 million in revenue over the twelve-month period ended September 30, 2019. The companies believe this business combination will provide increased revenue scale and enable operational synergies that can be leveraged to accelerate the combined company's growth and path to profitability. Aytu will also take over the outstanding notes payable of Innovus whichis expected to be approximately $3.2 million.

Upon closing, Aytu expects to operate the commercial aspects of the Innovus consumer business separately from Aytu's prescription business, while rationalizing general and administrative expenses through the removal of Innovus' public company costs and redundant administrative and operational processes, along with the reduction in overhead, administrative and facilities costs.

Aytu's prescription product portfolio will continue to be primarily commercialized through the existing Aytu sales force, while the consumer health products will continue to be primarily commercialized via Innovus' proprietary Beyond Human® marketing platform. However, both lines of business are expected to benefit from opportunistic cross-selling such that some consumer products may be marketed in the physician office setting by Aytu's sales force, while the marketing of the prescription products may be bolstered through various online and direct-to-consumer marketing initiatives.

At the time of signing the definitive agreement, Aytu had collected voting agreements supporting the merger transaction that represent approximately 35% of current shares outstanding. Innovus has thus far collected voting agreements supporting the transaction that represent approximately 24% of shares outstanding.

The acquisition is expected to close by February 14, 2020 if both companies' shareholders approve the transaction.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharmaceuticals is an emerging over the counter ("OTC") consumer goods and specialty pharmaceutical company commercializing, licensing and developing safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality. The Company is dedicated to being a leader in developing and marketing new OTC medicines and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription to OTC.

No Offer or Solicitation

Communications in this news release do not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction or otherwise, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Communications in this news release do not constitute a notice of redemption with respect to or an offer to purchase or sell (or the solicitation of an offer to purchase or sell) any security of Innovus.

Additional Information and Where to Find It

In connection with the proposed transaction between Aytu and Innovus, Aytu and Innovus will file relevant materials with the Securities and Exchange Commission (the "SEC"), including an Aytu registration statement on Form S-4 that will include a joint proxy statement of Aytu and Innovus that also constitutes a prospectus of Aytu, and a definitive joint proxy statement/prospectus will be mailed to shareholders of Aytu and Innovus. INVESTORS AND SECURITY HOLDERS OF AYTU AND INNOVUS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by Aytu or Innovus through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Aytu will be available free of charge on Aytu's internet website at https://irdirect.net/AYTU under the heading "SEC Filings" or by contacting Aytu's investor relations contacts at (646) 755-7412 or james@haydenir.com. Copies of the documents filed with the SEC by Innovus will be available free of charge on Innovus' internet website at https://innovuspharma.com/Investors/ under the heading "SEC Filings" or by contacting Innovus' investor relations at ir@innovuspharma.com.

Certain Information Regarding Participants

Aytu, Innovus, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Aytu is set forth in its Annual Report on Form 10-K for the year ended June 30, 2019, which was filed with the SEC on September 26, 2019. Information about the directors and executive officers of Innovus is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on April 1, 2019 and its proxy statement for its 2019 annual meeting of shareholders, which was filed with the SEC on April 30, 2019. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at http://www.sec.gov and from Investor Relations at Aytu or Innovus as described below.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements, including but not limited to any statements regarding the expected timetable for completing the proposed transaction, the results, effects, benefits and synergies of the proposed transaction, future opportunities for the combined company, future financial performance and condition, guidance and any other statements regarding Aytu's or Innovus' future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: failure to obtain the required votes of Innovus' shareholders or Aytu's shareholders to approve the transaction and related matters, the risk that a condition to closing of the proposed transaction may not be satisfied, that either party may terminate the merger agreement or that the closing of the proposed transaction might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration may not be reflective of the current market price of Aytu's common stock on the closing date, the failure to meet the revenue and profitability milestones that trigger the CVRs such that Innovus shareholders never realize value from the CVRs, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the transaction, the diversion of management time on transaction-related issues, the ultimate timing, outcome and results of integrating the operations of Aytu and Innovus, the effects of the business combination of Aytu and Innovus, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, regulatory approval of the transaction, risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for AYTU Investors:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

Contact for INNV Investors:

Randy Berholtz
Innovus Investor Relations
(858) 249-7865
ir@innovuspharma.com

SOURCE: Aytu BioScience, Inc.

ReleaseID: 574118

HOUSTON, TX / ACCESSWIRE / January 27, 2020 / PEDEVCO Corp. (NYSE American:PED) ("PEDEVCO" or the "Company") announced today that it has been awarded the "Best Independent Company – North America – 2019" by World Finance Magazine Oil and Gas Awards. This prestigious award recognizes PEDEVCO's innovation and accomplishments as an independent North American oil and gas company.

J. Douglas Schick, President of the Company, commented, "We are honored to receive this award which recognizes PEDEVCO's independent spirit and is a testament to the hard work and dedication of all of our employees, further validating our forward-thinking business model of developing conventional assets using unconventional new and emerging technologies. This past year was filled with significant accomplishments including accretive acquisitions of producing assets adjacent to PEDEVCO in the San Andres play of the Permian Basin, multiple private offerings and debt conversions to strengthen the balance sheet and a successful drilling program that significantly increased production and producing reserves. Given our strong liquidity position, zero debt, and inventory of over 150 drilling locations in our Permian Basin asset, we plan to carry this positive momentum into 2020 and continue to build shareholder value. We look forward to continuing our development plans, inspired by the honor of this prestigious award and mindful of the responsibility it carries."

The complete list of the 2019 World Finance Oil and Gas Awards can be viewed at: www.worldfinance.com/awards/oil-gas-awards-2019.

About World Finance

World Finance is a critically acclaimed magazine and website providing in-depth coverage and analysis of the financial industry and global economy. The editorial board combines award-winning reportage from in-house journalists and correspondents with contributions from some of the most influential economic and political thinkers of modern times. With subscription surpassing 120,000 readers, the magazine is globally recognized for the part it plays in shaping contemporary thought and the way the world looks at the worldwide financial sector.

About PEDEVCO Corp.

PEDEVCO Corp. (NYSE American: PED), is a publicly-traded energy company engaged in the acquisition and development of strategic, high growth energy projects in the United States. The Company's principal assets are its San Andres Asset located in the Northwest Shelf of the Permian Basin in eastern New Mexico, and its D-J Basin Asset located in the D-J Basin in Weld and Morgan Counties, Colorado. PEDEVCO is headquartered in Houston, Texas.

Cautionary Statement Regarding Forward Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Acts"). In particular, when used in the preceding discussion, the words "estimates," "believes," "hopes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 and subsequently filed Quarterly Reports on Form 10-Q under the heading "Risk Factors". The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements, except as otherwise required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the Securities Exchange Commission (SEC).

Contacts

PEDEVCO Corp.
1-855-733-3826
PR@pedevco.com

SOURCE: PEDEVCO Corp.

ReleaseID: 574052

CALGARY, ALBERTA / ACCESSWIRE / January 27, 2020 / CANEX Metals Inc. ("CANEX" or the "Company") is pleased to announce results for grid soil sampling conducted in December 2019 at the Gold Range Property, Arizona.

Three test soil grids were sampled over portions of the Central and East Zones containing gentle to rolling topography and limited rock outcrop. On average soil samples were taken every 10 metres on sample lines spaced 25, 50, or 100 metres apart. A total of 425 soil samples were taken with gold results ranging from <2 parts per billion (ppb) to 5710 ppb, averaging 38 ppb.

Highlights of the Test Soil Sampling

Soil results have successfully identified large gold targets open for expansion.
A gold in soil anomaly 330 metres long (and open) by 90 metres wide correlates with magnetic lows and measured vein orientations.
Soil values up to 5710 and 1290 ppb gold are scheduled for near term follow up.

The test grids have successfully identified large and open gold in soil anomalies and further support the potential for large and continuous gold bearing vein targets through the area. The Gold Range Property contains high-grade gold vein mineralization over a 5 km by 3 km area that has not been assembled and systematically explored previously. The Company's objective at Gold Range is to utilize modern exploration techniques including structural analysis to target zones with the best potential for large high-grade zones of gold mineralization. Surface soil sampling will clearly help with that objective.

A map showing the location of the grids and simplified gold in soil results is available here.

Dr. Shane Ebert, President of the Company stated, "We are very pleased to see our surface rock sampling and mapping, airborne magnetics, and now soil geochemistry all coming together to demonstrate multiple exploration targets on the Gold Range Property each with good size potential. The 330 metre long by 90 metre wide gold in soil anomaly at test Grid 1 in the Central area remains open for expansion along strike and adds another quality target that we anticipate can be advanced to the drill testing stage in a cost effective and timely manner. Several of the gold in soil anomalies show a correlation with airborne magnetic lows demonstrating the value of both exploration techniques in our ongoing evaluation of the property."

Exploration Update

In December detailed sampling was conducted at the Pit Zone and at several other targets on the Gold Range property. Over 100 rock samples were collected and submitted for assay, with results pending. These will be released once they are received and evaluated. Follow up high resolution drone magnetic surveying has recently been completed over two key target areas with results expected shortly.

Near-term plans for additional field work at Gold Range will be finalized once rock sample results have been received and targets from airborne magnetics prioritized. The Company has filed an appended exploration permit application with the Bureau of Land Management to allow for an expanded trenching and drilling program to include several new targets recently identified on the property. Once the amended permit has been received a second trenching program is anticipated.

Quality Control

The soil samples reported here were taken by a contract geological services company with all samples delivered to ALS USA Inc. in Elko, Nevada (which is ISO/IEC 17025 accredited). For each sample approximately 0.5 kg of material was sampled from 10 to 25 centimeters depth along pre-determined sample grids. Four hundred and forty-one samples were delivered to ALS including 425 soil samples, 9 standards and 7 duplicates. Gold was assayed using a 30g fire assay (method Au-ICP21) with an ICP-AES finish.

About the Gold Range Property

The Gold Range Property is located in Northern Arizona within an area that has seen historic lode and placer gold production but limited systematic modern lode gold exploration. Fieldwork by the Company has identified numerous gold exploration targets on the property with grab samples from outcropping quartz veins returning multiple values in the 20 to 40 g/t gold range, and chip sampling returning values of 28.1 g/t gold over 1 metre and 8.47 g/t gold over 5.6 metres. Please visit our website at www.canexmetals.ca for additionnel information.

Dr. Shane Ebert P.Geo., is the Qualified Person for CANEX Metals and has approved the technical disclosure contained in this news release.

"Shane Ebert"

Shane Ebert

President/Director

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Except for the historical and present factual information contained herein, the matters set forth in this news release, including words such as "expects", "projects", "plans", "anticipates" and similar expressions, are forward-looking information that represents management of CANEX Metals Inc. internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the economic performance of CANEX. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause CANEX's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, those described in CANEX's filings with the Canadian securities authorities. Accordingly, holders of CANEX shares and potential investors are cautioned that events or circumstances could cause results to differ materially from those predicted. CANEX disclaims any responsibility to update these forward-looking statements.

For Further Information Contact:

Shane Ebert at 1.250.964.2699 or
Jean Pierre Jutras at 1.403.233.2636
Web: http://www.canexmetals.ca

SOURCE: CANEX Metals Inc.

ReleaseID: 574155

Backlog expected to reach $66.2 Million at December 31, 2019, led by 50% Increased Bookings at PM Group

BRIDGEVIEW, IL / ACCESSWIRE / January 27, 2020 / Manitex International, Inc. (NASDAQ:MNTX), a leading international provider of cranes and specialized industrial equipment, today announced a strengthening in orders in the fourth quarter that management anticipates will result in a reported backlog of $66.2 million for the period ended December 31, 2019, growing from $57.6 million as of September 30, 2019.

The recovery in the backlog was driven primarily by the company's articulated crane group, which saw an increase in orders during the fourth quarter, with particular strength from North America, Western Europe and Latin America. Management currently expects to announce a 50% increase in backlog at year end for this product group to $24.8 million, consisting of PM, Manitex Articulating Cranes ("MAC"), Tadano-PM branded articulating cranes, Oil & Steel Aerials, and Valla industrial Cranes.

"While the backlog for our straight-mast crane business decreased 5% due to lower levels of activity in certain parts of the construction markets, progress in executing our North American branding and distribution strategy for the MAC line provided significant year over year growth for our articulated crane business. We anticipate growth for the MAC line in North America to continue as we move through 2020," said Steve Kiefer, President and COO for Manitex International.

"Key organizational and operational improvements we have made within the PM Group, to enhance our focus, quality, productivity, and overall financial performance have resulted in more meaningful participation in large global growth markets that we have long-identified as key to our company's future success. The three-brand strategy we've launched for our articulated cranes, namely PM, MAC, and Tadano-PM, is showing early signs of success and we are closing in on an annualized revenue rate of over $100 million for this group," said Steve Filipov, Chief Executive Officer for Manitex International.

Manitex looks forward to participating in the upcoming CONEXPO show, being held in Las Vegas, on March 10-14, where team leaders will be showcasing new MAC-branded products, enhancements to the Manitex line of straight mast cranes, its latest industrial cranes, and the North American debut of the Valla V80R zero emissions pick-and-carry crane. Attendees are encouraged to visit Booth # F6259 for a demonstration.

About Manitex International, Inc.

Manitex International, Inc. is a leading worldwide provider of highly engineered mobile cranes (truck mounted straightmast and knuckle boom cranes, industrial cranes, rough terrain cranes and railroad cranes), truck mounted aerial work platforms and specialized industrial equipment. Our products, which are manufactured in facilities located in the USA and Europe, are targeted to selected niche markets where their unique designs and engineering excellence fill the needs of our customers and provide a competitive advantage. We have consistently added to our portfolio of branded products and equipment both through internal development and focused acquisitions to diversify and expand our sales and profit base while remaining committed to our niche market strategy. Our brands include Manitex, PM, Oil & Steel, Badger, Sabre, and Valla.

Forward-Looking Statements

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Contact:

Manitex International, Inc.
Steve Filipov
Chief Executive Officer
(708) 237-2054
sfilipov@manitex.com

Darrow Associates, Inc.
Peter Seltzberg, Managing Director
Investor Relations
(516) 419-9915
pseltzberg@darrowir.com

SOURCE: Manitex International Inc.

ReleaseID: 574172

Alpine 4 Technologies' (OTCQB:ALPP) subsidiary Deluxe Sheet Metal, Inc. (DLX), today announced that it has secured two new projects totaling $1.0 million with one of its university customers for new building projects for the university in 2020

PHOENIX, AZ / ACCESSWIRE / January 27, 2020 / Deluxe Sheet Metal Inc. has provided mechanical contracting to its customers around in the US since 1956.

Kent Wilson CEO of Alpine 4 had this to say, "These two contracts totaling $1m will add nicely to an ever-growing backlog of work for Deluxe which we believe will lead to solid revenue numbers for Deluxe in 2020 and 2021.

Jason Sergeant VP of Operations of Deluxe Sheet Metal had this to say; "Deluxe is already stacking up great work for 2020, but these two new projects with one of our long-term customers will ensure a very successful 2020 for both Deluxe and Alpine 4."

About Alpine 4 Technologies:

Alpine 4 Technologies, Ltd (ALPP) is a publicly traded conglomerate that is acquiring businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. At Alpine 4, we understand the nature of how technology and innovation can accentuate a business. Our focus is on how the adaptation of new technologies, including brick and mortar businesses, can drive innovation. We also believe that our holdings should benefit synergistically from each other and that the ability to have collaboration across varying industries can spawn new ideas and create fertile ground for competitive advantages.

Ian Kantrowitz: Director of IR
investorreleations@alpine4.com

Forward-Looking Statements:

The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.

SOURCE: Alpine 4 Technologies, Ltd

ReleaseID: 574133

OLD BRIDGE, NJ / ACCESSWIRE / January 27, 2020 / Blonder Tongue Laboratories, Inc. (NYSE American:BDR) announced today the appointment of John Burke to its board of directors.

Mr. Burke is a seasoned senior operating executive with more than 25 years' experience working with both large-scale and emerging businesses. He currently serves as a Managing Partner of Vetust Advisors, which provides strategic and management consulting services to a variety of businesses. Mr. Burke previously served as Executive Vice President and Chief Operating Officer of Rovi Corporation (since re-named TiVo) from 2014 to 2016, where he led the transformation of the company's content discovery, user interface, and data analytics businesses, including the acquisition of TiVo. Prior to joining Rovi, he led a number of different businesses for ARRIS Group, Motorola, Motorola Mobility and General Instrument. Mr. Burke also is an active investor, advisor, and board member to several early stage companies focused on data analytics, machine learning, and workforce optimization.

Mr. Burke holds a Bachelor of Science in Business Administration from The Ohio State University, a Masters of Business Administration from St. Joseph's University and attended the Executive Leadership Program at Northwestern University's Kellogg School of Business.

Commenting on Mr. Burke's appointment, Steven Shea, Blonder Tongue's Chairman of the Board said: "We are extremely pleased to welcome John Burke to our Board of Directors. John's record of strategic and operational leadership and intimate, in-depth knowledge of the cable, video and communications markets puts him in the position to provide us valuable guidance on product, market and strategic matters."

About Blonder Tongue

Blonder Tongue Laboratories, Inc. is the oldest designer and manufacturer of cable television video transmission technology in the USA. The majority of our products continue to be designed and built in our state-of-the-art New Jersey facility for over 50 years. The company offers U.S. based engineering and manufacturing excellence with an industry reputation for delivering ultra-high reliability products. As a leader in cable television system design, the company provides service operators and systems integrators with comprehensive solutions for the management and distribution of digital video, IPTV and high-speed data services, as well as RF broadband distribution over fiber, IP, and Coax networks for homes and businesses. Additional information on the company and its products can be found at www.blondertongue.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes "forward-looking" statements and accordingly, the cautionary statements contained in Blonder Tongue's Annual Report and Form 10-K for the year ended December 31, 2018. (See Item 1: Business, Item 1A: Risk Factors, Item 3: Legal Proceedings and Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations), and other filings with the Securities and Exchange Commission are incorporated herein by reference. The words "believe", "expect", "anticipate", "project", "target", "intend", "plan", "seek", "estimate", "endeavor", "should", "could", "may" and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, our anticipated growth trends in our business and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. Blonder Tongue undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Blonder Tongue's actual results may differ from the anticipated results or other expectations expressed in Blonder Tongue's "forward-looking" statements.

Contacts

Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000

Ted Grauch
Chief Executive Officer
tgrauch@blondertongue.com
(732) 679-4000

SOURCE: Blonder Tongue Laboratories, Inc.

ReleaseID: 574112

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / Margaret Lake Diamonds Inc. ("Margaret Lake" or the "Company") (TSX.V:DIA)(FKT:M85) and KORID Energy Company Inc. ("KORID"), a subsidiary of DST Inc. ("DST") (KOSDAQ: 033430), are pleased to announce a joint venture to construct a factory (the "Factory") in the United States for the purpose of producing Vanadium Redox Flow Batteries and energy storage systems (the "Joint Venture"). Executives of Margaret Lake and KORID along with past and current officials of the State of New York met in New York City for the signing of the joint venture agreement. The planned Phase I capacity of the Factory is 50MW output and 200MWh of storage.

Pictured standing from L to R: Yunki Kim, President, DST, Kyonglock Na, Head of R&D,KORID, Jason Kuh, Vice-chairman, DST Group, George Pataki, Former Governor of NY State, John Kerry, President, John Kerry Energy Solutions, Neil Foran, CFO, Margaret Lake. Seated L to R are Paul Kim, Chairman DST Group and President of KORID, Jared Lazerson, CEO and President of Margaret Lake.

Opening remarks by John Kerry and former New York Governor George Pataki are available at https://youtu.be/KIre7TMNb5k

JOINT VENTURE

The Joint Venture grants exclusive global rights to KORID's proprietary vanadium redox battery technology, with the exception of Korea and Australia, to Margaret Lake. In addition, KORID will provide technical assistance for design, construction and operation of the Factory. In consideration Margaret Lake has agreed to the following terms:

Margaret Lake will complete a consolidation of its outstanding shares on a 1 new share for every 5.468 old shares basis, resulting in shares outstanding of 10,001,205;
Margaret Lake will raise $5,000,000 at a price of $0.25 resulting in an issuance of 20,000,000 post-consolidation shares of Margaret Lake;
KORID, DST Inc. and Protean Energy Ltd. will receive an aggregate 20,000,000 post-consolidation shares of Margaret Lake in consideration for the exclusive technology license and technical assistance in design, construction, and operation of the Factory.

The Joint Venture will be implemented pursuant to the terms of a Joint Venture Agreement between the Company and KORID dated January 13, 2020. Implementation of the Joint Venture is subject to a number of customary closing conditions, including the approval of the TSX Venture Exchange. The Joint Venture is an Arm's Length Transaction under the policies of the TSX Venture Exchange.

Factory Design

Preliminary factory footprint, process flow, equipment and personnel requirements have been completed by KORID for Phase I of the Factory with an annual output capacity of 50MW and 200MWh of storage.

Battery Design

KORID's proprietary Vanadium Redox Flow Battery has been developed and tested over the past 10 years and is patent protected. The flow battery design allows for limitation of storage only based on the capacity of the electrolyte tanks versus the fixed capacity of lithium-ion. The battery is non-flammable and non-explosive. There is no degradation as a result of cycling, partial charging, or time with a 100% depth of discharge and projected lifetime of 20 years. Battery efficiency is currently rated at up to 80%. The battery is scalable into the MW-range through simple parallel connection of multiple units. The systems are shipped in self-contained weatherproof and securely protected housing. The systems can be managed and maintained by remote or online maintenance through intelligent battery management. Temperature management and climate controlled containers eliminates weather impact on energy efficiency.

The battery is composed of four primary components: electrolyte tanks, cell stacks, power conversion system (including control system, communications, inverter, electrical wiring, etc.), and pumps / balance of plant equipment (Figure 1). The systems are designed for containerized deployment in twenty or forty foot containers. The forty foot design has a capacity of 100kW output, 400kWh capacity.

Figure 1

Cell Stack

KORID has manufactured four cell stacks to date including 2.5kW, 5kW, 10kW, and 25kW (Figure 2). KORID has developed and is currently testing a 50kW cell stack for high usage industrial and grid scale utility and renewables applications.

Figure 2

Grid Scale Mass Storage

Designs have been completed for a 3.6MW output system (Figure 3) to meet the demand for grid scale applications. There are a variety of applications to support both renewables and existing infrastructure as well as energy security. Placing batteries at substations or near high demand areas reduces need for new infrastructure such as transmission lines, substation capacity, and traditional power plants or hydro dams. Generated power is often wasted in the night only for a lack of battery capacity. Grid scale energy storage systems allow for charging at night during very low demand times (off peak) and release that energy during the day during peak demand reducing the need for new transmission lines or power plants. This both increases overall efficiency and provides backup/standby power for energy security and a robust and efficient energy infrastructure.

Figure 3

About KORID Energy and DST Inc.

KORID is a subsidiary of DST Inc., a publicly traded company listed on the KOSDAQ Exchange in South Korea. It operates the following businesses: Automation Machinery, Mining and Metals Development and Processing, along with other diversified businesses. Its products and services include energy storage technologies, equipment for the automobile components industry, food processing equipment, mineral development and processing, rental services, and others. The company was founded in 1995 and is headquartered in Changwon-si, South Korea. For more information visit www.ds-t.co.kr.

About Margaret Lake Diamonds

Margaret Lake Diamonds Inc. (TSX.V: DIA) is a Canadian technology and strategic metals exploration company focused on construction of Vanadium Redox Flow Battery Factory and Vanadium Exploration in the United States. The Company continues to maintain an interest in its mining properties.

Contact Information

Jared Lazerson
President and CEO
jared@margaretlakediamonds.com
Web: www.margaretlakediamonds.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements (collectively "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: "believe", "expect", "anticipate", "intend", "estimate", "potentially" and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to the Company's public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company's profile on SEDAR at www.sedar.com.

SOURCE: Margaret Lake Diamonds Inc.

ReleaseID: 573840

JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with FOX Business Network for the following program:

"The Claman Countdown" (National)

FOX Business Network
Monday, January 27, 2020
Time: 3 – 4 p.m. ET
Host: Liz Claman

You will be able to view the live show on FOX Business Network or online by following the link below:

https://www.foxbusiness.com/shows/the-claman-countdown

Mr. Emalfarb was also interviewed by WPBF 25 News on Friday, January 24, 2020, urging US pharmaceutical manufacturers to step up vaccine production as coronavirus spreads. To view the interview, click on the following link:

https://www.wpbf.com/article/jupiter-biotech-ceo-urging-us-manufacturers-to-step-up-vaccine-production-as-corona-virus-spreads/30658798

About Liz Claman

Liz Claman joined FOX Business Network (FBN) as an anchor in October 2007. She anchors Claman Countdown (weekdays 3-4PM/ET). Her October debut on FBN included an exclusive interview with Berkshire Hathaway CEO and legendary investor Warren Buffett. Throughout her tenure at FBN, Claman has conducted exclusive interviews with every U.S. Treasury Secretary from John Snow to Paul O'Neill, Larry Summers, Timothy Geithner and Jack Lew. Claman has brought a roster of business leaders including JP Morgan CEO Jamie Dimon, Starbucks CEO Howard Schultz, Twitter co-founders Jack Dorsey, Evan Williams and Biz Stone, Google/Alphabet Executive Chairman Eric Schmidt, and Microsoft founder Bill Gates to Fox Business viewers as well as world leaders, including Israeli Prime Minister Benjamin Netanyahu and Ukraine President Petro Poroshenko. Prior to joining FBN, Claman served as an anchor at CNBC, most recently anchoring Morning Call and Wake Up Call, Market Watch, and Today's Business. During her time at CNBC, Claman landed the first one-hour live one-on-one interview with Warren Buffett. Before CNBC, Claman, a two-time Emmy Award winner, served as an anchor and reporter for Boston's WHDH-TV (NBC). She was also a contributing correspondent for NBC's syndicated daytime program RealLife. Prior to that, she anchored a two-hour daily talk show, The Morning Exchange for WEWS-TV (ABC) in Cleveland. She received an Emmy for her work on The Morning Exchange. A graduate of the University of California, Berkeley and the Sorbonne in Paris, Claman began her on-air career at WSYX-TV (ABC) in Columbus, OH as a reporter and later a weekend anchor. Earlier, she was a news associate for KCBS-TV (CBS) in Los Angeles where she was the youngest person in the station's history to win a local Emmy Award for Best Spot News Producer. Claman is a member of the Board of Directors of the American Theatre Wing and is a Tony Award voter. She is an active fundraiser for Building Homes for Heroes, an organization that builds mortgage-free homes for severely wounded soldiers returning from Iraq and Afghanistan. She has completed 7 triathlons and one New York City marathon.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website at http://www.dyadic.com

Contact:
Dyadic International, Inc.
Mark Emalfarb, CEO
Phone: +1 (561) 743-8333
Email: memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 574169

LOS ANGELES, CA / ACCESSWIRE / January 27, 2020 / MCTC Holdings, Inc. (OTC PINK:MCTC), a company developing unique hemp infusion technologies and cannabinoid delivery systems, today announces a new system to enable coffee and other beverage companies to easily produce clean label hemp extract and cannabidiol (CBD) single-serving coffee and beverage pods. The product offering, which is based on two recently filed patents, will allow coffee manufacturers to produce coffee pods with precisely measured amounts of hemp extracts, CBD, or other cannabinoids and avoid the complexities of CBD infusions and potency testing.

Named Hemp You Can Feel™ Coffee Infusions, the product is available in two formats. The first is a tablet containing hemp infusions and other ingredients that can be customized by the customer. The manufacturer simply adds the tablet to the coffee pod during the manufacturing process. Powdered forms are also available for manufacturers with automated capabilities. Whether in tablet or powder form, both include dual infusion technologies that use no chemical additives, surfactants or other processing additives. Upon contact with water, the cannabinoids and other ingredients are infused directly into the beverage with near 99% efficiency with minimal or no effect on the taste or other characteristics of the beverage.

"We are now offering single-serving coffee manufacturers a superior method to infuse products with CBD and other cannabinoids," commented Arman Tabatabaei, CEO of MCTC Holdings. "It is so revolutionary, we have filed two patents; one on the underlying powderization technology and another on the use of solid and powdered dosing forms for cannabinoids in single-serving beverage pods. With our new products, manufacturers are able to precisely dose each pod with the exact amount of active ingredient desired. The technology is easily customizable to suit the particular requirements of the application. With the product offering, even the smallest of single-serving pod manufacturers will be able to easily transform ordinary low margin products into products that are high margin and very profitable."

Hemp You Can Feel™ Coffee Infusions are designed for ease of use, dosing accuracy and high bioavailability. The product utilizes two infusion technologies, both of which allow for clean labeling of products as no chemical additives of any kind are utilized. Whereas the vast majority of hemp extract infusions rely on surfactants, chemicals and harsh processing to force the oil-based hemp extracts to mix with the water-based and powdered elements, the Company has developed and applied for patents on new technologies that utilize only organic, natural and non-GMO ingredients.

Mr. Tabatabaei continued, "It is truly scary what many CBD manufacturers are using to infuse CBD into products. With this product, we offer superior infusion technologies and unparalleled ease of use. We have designed the system to eliminate the complex measuring, mixing and testing required to properly infuse CBD into products. We provide everything in a premixed form that is simply added to the pod – we even provide a full certificate of analysis from third-party laboratories that can be included in product packaging to provide comfort to consumers that they are getting the potency and purity they deserve. Not only is this infusion system likely vastly superior to most processes currently being deployed, it is also likely a less expensive solution compared to attempting the complex infusion process in house. Simply put – this will be a superior and likely less expensive method to infuse CBD into single-serving beverage products."

The Hemp You Can Feel™ Coffee Infusions are based on the Company's patent-pending Hemp You Can Feel™ technology, which utilizes no chemical surfactants or stabilizers and requires no high shear processing, sonication, spray drying or other harsh extract manipulations, all of which are common legacy processing technologies. Additionally, the technology contains no artificial colors, dyes, or preservatives and most importantly, there is no detectable hemp taste and no THC.

The Company has recently filed six patents on hemp extract technologies and delivery systems. MCTC is currently working with patent counsel to protect various other aspects of its new technologies. As previously announced, the Company plans to continue other areas of delivery systems research including its programs pertaining to polymeric cannabinoid nanoparticles and nanofibers. Additionally, MCTC has recently announced a varin cannabinoid R&D program concentrating on glycosides. The technologies being announced today are non-nanoparticle based.

About MCTC Holdings, Inc.

MCTC Holdings, Inc. (d/b/a: Cannabis Global) is a Delaware registered, fully reporting and audited publicly-traded company. With the hemp and cannabis industries moving very quickly and with a growing number of market entrants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The Company plans to actively pursue R&D programs and productization for exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers for addition into consumer products and for dermal application. The Company was reorganized during June of 2019 and announced its intent to enter the fast-growing cannabis sector and its intent to change its corporate identity to Cannabis Global, Inc. The Company is headed and managed by a group of highly experienced cannabis industry pioneers and entrepreneurs.

More information on the Company can be viewed at www.CannabisGlobalinc.com.

For more information, please contact:

Arman Tabatabaei
IR@cannabisglobalinc.com

Forward-looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

SOURCE: MCTC Holdings, Inc

ReleaseID: 574162